Stay updated on IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial page.

Latest updates to the IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe study's enrollment status was updated to 'No longer looking for participants', indicating recruitment has closed. New help and navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment label styling was adjusted along with the revision note updated to v3.6.0.SummaryDifference0.4%

- Check14 days agoChange DetectedThe page now shows Revision: v3.5.5, replacing Revision: v3.5.4, indicating an update to the page. This update does not affect the study content or presentation of information.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedUpdated the page's revision from v3.5.3 to v3.5.4, reflecting a minor update to the page's version metadata. This change indicates a new build or refresh of the page rather than a modification to its substantive content.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page’s revision/version label has been updated from v3.5.2 to v3.5.3 at the bottom of the study details page.SummaryDifference0.0%

- Check64 days agoChange Detected- Revision updated from v3.5.0 to v3.5.2. This change does not alter study information or visible page content.SummaryDifference0.0%

- Check93 days agoChange DetectedAdded multiple Spain-based site locations (Sevilla, Madrid, Lleida, Barcelona, Valencia) and updated the study revision/version. Removed prior contact details and recruitment status notes for several sites.SummaryDifference4%

Stay in the know with updates to IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IPATHER: PI3KCA-mutant Breast Cancer Clinical Trial page.